Diffuse Large B-Cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co

Diffuse Large B-Cell Lymphoma Pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-Cell Lymphoma treatment therapies, analyzes DelveInsight.

Diffuse Large B-Cell Lymphoma Overview:

Diffuse large B cell lymphoma (DLBCL) is the most prevalent type of non-Hodgkin lymphoma, representing around 25% to 30% of all cases. It usually presents with rapidly growing lymph nodes or masses, which can be nodal or extranodal. DLBCL originates from the malignant growth of B cells, typically from germinal center B cells. Factors such as genetic mutations, chronic immunodeficiency, and infections like Epstein-Barr virus can contribute to its development. DLBCL is heterogeneous, with several molecular subtypes identified through gene expression profiling. Its pathophysiology involves the dysregulation of genes like BCL2, BCL6, and MYC. Treatment generally includes immunochemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with the treatment plan tailored based on molecular subtype and clinical stage. Despite its aggressive nature, DLBCL can lead to long-term remission with proper treatment, emphasizing the importance of early diagnosis and comprehensive care.

Symptoms of DLBCL can vary but often include rapidly enlarging lymph nodes or masses, which can be nodal or extranodal. Patients may experience B symptoms such as fever, night sweats, and weight loss, which occur in about 30% of cases. Bone marrow involvement is common in up to 50% of patients, and extranodal involvement is seen in approximately 50% of cases. DLBCL can present with symptoms related to the compression of nearby structures, such as superior vena cava syndrome or airway obstruction, particularly in cases with extranodal disease. Systemic symptoms (B-symptoms) may also occur due to increased cytokine production. The presentation can vary depending on whether the lymphoma subtype is aggressive or indolent, with aggressive forms typically showing rapidly growing masses, while indolent lymphomas may progress more slowly with intermittent or worsening lymphadenopathy.

Request for a detailed insights report on Diffuse Large B-Cell Lymphoma pipeline insights @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Diffuse Large B-Cell Lymphoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diffuse Large B-Cell Lymphoma Therapeutics Market.

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
In April 2024, Rituxan (rituximab) was approved for the treatment of various blood cancers, autoimmune disorders, and inflammatory conditions, such as follicular lymphoma (FL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris (PV). Additionally, RITUXAN HYCELA, a formulation combining rituximab with Halozyme's hyaluronidase human ENHANZE technology, was approved for adults with previously untreated or relapsed/refractory FL, untreated DLBCL, and both untreated and treated CLL.
In March 2024, Lantern Pharma began dosing two participants in a Phase Ia/Ib clinical trial for LP-284, an experimental drug for relapsed or refractory NHL. LP-284 is an innovative small molecule designed to target and eliminate cancer cells with mutations in DNA damage repair pathways through a synthetically lethal approach.
In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm trial of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met their primary endpoint of overall response rate, with Breyanzi demonstrating statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies.
In May 2023, Genmab A/S revealed that the U.S. Food and Drug Administration (FDA) approved EPKINLY™ (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, following two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had rejected a proposal from Janssen Biotech, Inc. to continue their collaboration and option agreement under new terms. As a result, the agreement was terminated, and all collaboration activities were scheduled to wind down by the first quarter of 2023.
Key Diffuse Large B-Cell Lymphoma companies such asMiltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating new drugs for Diffuse Large B-Cell Lymphoma to improve the treatment landscape.
Promising Diffuse Large B-Cell Lymphoma pipeline therapies in various stages of development include Brentuximab vedotin, Abexinostat, RNK05047, BMF-219, ADI-001, THOR-707, and others.

Diffuse Large B-Cell Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Diffuse Large B-Cell Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.

Download our free sample page report on Diffuse Large B-Cell Lymphoma pipeline insights @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diffuse Large B-Cell Lymphoma Emerging Drugs

Brentuximab vedotin: Pfizer
Abexinostat: Xynomic Pharmaceuticals
RNK05047: Ranok Therapeutics
BMF-219: Biomea Fusion
ADI-001: Adicet Bio
THOR-707: Sanofi

Diffuse Large B-Cell Lymphoma Companies

Over 70 key companies are working on developing therapies for Diffuse Large B-Cell Lymphoma. Among them, Pfizer has its drug candidates for this condition in the most advanced stage, Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Diffuse Large B-Cell Lymphoma Therapies and Key Companies: Diffuse Large B-Cell Lymphoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Diffuse Large B-Cell Lymphoma Pipeline Therapeutic Assessment
• Diffuse Large B-Cell Lymphoma Assessment by Product Type
• Diffuse Large B-Cell Lymphoma By Stage
• Diffuse Large B-Cell Lymphoma Assessment by Route of Administration
• Diffuse Large B-Cell Lymphoma Assessment by Molecule Type

Download Diffuse Large B-Cell Lymphoma Sample report to know in detail about the Diffuse Large B-Cell Lymphoma treatment market @ Diffuse Large B-Cell Lymphoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Diffuse Large B-Cell Lymphoma Current Treatment Patterns
4. Diffuse Large B-Cell Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Diffuse Large B-Cell Lymphoma Late-Stage Products (Phase-III)
7. Diffuse Large B-Cell Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diffuse Large B-Cell Lymphoma Discontinued Products
13. Diffuse Large B-Cell Lymphoma Product Profiles
14. Diffuse Large B-Cell Lymphoma Key Companies
15. Diffuse Large B-Cell Lymphoma Key Products
16. Dormant and Discontinued Products
17. Diffuse Large B-Cell Lymphoma Unmet Needs
18. Diffuse Large B-Cell Lymphoma Future Perspectives
19. Diffuse Large B-Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Diffuse Large B-Cell Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.